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Abstract
We determined the mutation frequencies of 59 nosocomial isolates of Enterobacter cloacae, and investigated their association with anti-
microbial susceptibility, genotype, and history of exposure to antimicrobials. The frequencies of mutations leading to rifampicin resis-
tance ranged from 5.8 · 10)9 to 8.0 · 10)6 (median, 5.0 · 10)8). Seven of the 59 (12%) isolates were graded as strong mutators
exhibiting a more than 50-fold increase in the mutation frequency relative to that of E. cloacae ATCC 13047, and 30 (52%) were graded
as weak mutators exhibiting a more than ﬁve-fold and not more than 50-fold increase in the mutation frequency. The isolates with
higher grade of mutation frequency were resistant to signiﬁcantly more antimicrobials (medians of two, one and zero agents for strong
mutators, weak mutators and non-mutators, respectively; p 0.0078). The 59 isolates were classiﬁed into 36 genotypes, and all of the
seven strong mutators had distinct genotypes. Mutation frequencies varied more than 102-fold within a clone. In patient-based, univari-
ate analysis, intensive-care unit admission, dense antimicrobial exposure (glycopeptide or multiple classes) and repetitive detection of
this species were signiﬁcantly more common among all of the four patients from whom strong mutators were obtained. Strong muta-
tors are highly prevalent in surgical isolates of E. cloacae. Higher mutation frequency was associated with antimicrobial resistance and
repetitive detection, and may contribute to the adaptability of this species.
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Introduction
Mutators (bacterial strains with increased mutation rates) in
bacterial populations are thought to facilitate the bacterium’s
adaptation to diverse environmental ‘stress factors’, such as
antimicrobial challenge [1,2]. The role of mutation in the
acquisition of antimicrobial resistance has been investigated
in various species of bacteria. Mutations in the genes encod-
ing the targets of antimicrobials result in resistance to cer-
tain agents [3]. Mutations suppressing expression of the
OprD porin of Pseudomonas aeruginosa reduce the perme-
ability of the cell wall to carbapenems [4]. Genes that regu-
late the expression of chromosomal type C b-lactamases
are also reported to be inﬂuenced by mutation, leading to
constitutive hyperproduction of the enzyme, which makes
the isolates resistant to expanded-spectrum cephalosporins
[5].
Only 1% or fewer of natural isolates of Escherichia coli and
Salmonella species display increases in their mutation fre-
quencies of more than 50-fold relative to those of control
strains [6,7], and none of environmental P. aeruginosa isolates
exhibit mutation frequencies 20-fold or greater than that of
PAO1 [8]. In clinical settings, more than 50% of P. aeruginosa
isolates from the lungs of patients with chronic lung diseases
were mutators, and their phenotypes exhibited a strong
association with multiple drug resistance [9]. Inactivation of
the mismatch repair system favours persistence of P. aerugin-
osa in cystic ﬁbrosis mice [10], and accumulation of adaptive
mutations plays a major role in the genetic evolution of
P. aeruginosa isolates obtained from cystic ﬁbrosis patients
[11].
Enterobacter cloacae, one of the major causes of nosoco-
mial infection [12], has been reported to show increasing
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resistance to multiple antimicrobials. The prevalence of
mutators in this species and their clinical impact, however,
have not been investigated [13].
In this article, we describe the mutation frequencies of
clinical isolates of E. cloacae and their association with anti-
microbial susceptibility and genotype. We also analysed the
characteristics of the patients to ﬁnd the ‘stress factors’
associated with detection of mutators in the clinical
settings.
Materials and Methods
Study isolates, study period, and clinical background
E. cloacae isolates were collected consecutively from the in-
patients of the Department of Surgery at Kyoto University
Hospital from January to July 2003. Species identiﬁcation was
performed with the VITEK Gram-Negative Identiﬁcation
Card and API 20E (bioMe´rieux, St Louis, MO, USA), accord-
ing to the manufacturer’s instructions. MICs of the ﬁve
selected antimicrobials—piperacillin–tazobactam, ceftazidime,
imipenem, gentamicin, and levoﬂoxacin—were determined
by the broth microdilution method, according to the CLSI
guidelines [14].
Information on characteristics of the patients was col-
lected from their medical records, and included gender, age,
history of intensive-care unit (ICU) admission, type of sur-
gery (transplantation or not), and systemic administration of
b-lactam, aminoglycoside, ﬂuoloquinolone and glycopeptide
antimicrobials in the study period. The isolates obtained
from each patient at intervals of 30 days or more were
included repeatedly in the study to investigate the relation-
ship between the mutation frequency and repetitive detec-
tion of E. cloacae.
Determination of mutation frequencies and deﬁnition and
classiﬁcation of mutators
Mutation frequencies were determined with the method
reported by Oliver et al. [15], with modiﬁcations. Brieﬂy, a
single colony of E. cloacae was resuspended in 20 mL of
Mueller–Hinton (MH) broth (Eiken Chemical Co., Ltd,
Tokyo, Japan), and grown overnight at 37C. After centrifu-
gation, the pellet was resuspended in 1 mL of sterile saline.
Serial ten-fold dilutions were inoculated onto MH agar plates
with and without 100 mg/L rifampicin (Sigma-Aldrich, Inc.,
St Louis, MO, USA). After 48 h of incubation at 37C, the
colonies were counted and the fractions of CFUs on the rif-
ampicin-containing plates were calculated. To exclude the
possibility of a pre-existing rifampicin-resistant subpopulation,
approximately 107 CFUs of each isolate cultured on a rifam-
picin-free plate were inoculated onto MH agar plates con-
taining 100 mg/L rifampicin, and absence of growth was
conﬁrmed. We determined the mutation frequency of Escher-
ichia coli ATCC 25922 to conﬁrm the compatibility of our
experiment with previous studies [6,7,16].
All experiments were performed in triplicate. We adopted
the mean of the triplicate result as the mutation frequency
for each isolate, and repeated the experiment when the vari-
ation in mutation frequency among the triplicate experiments
was more than ten-fold. Each of the isolates was classiﬁed as
either a ‘strong mutator’, a ‘weak mutator’, or a ‘non-muta-
tor,’ according to the increase in mutation frequency relative
to the E. cloacae control strain, ATCC 13047. Isolates that
exhibited a >50-fold increase in mutation frequency were
deﬁned as strong mutators, and were given a score of 3; iso-
lates with mutation frequencies of between >5-fold and £50-
fold were classiﬁed as weak mutators, and were given a
score of 2; and the remaining isolates, with £5-fold increase
in mutation frequency, were classiﬁed as ‘non-mutators’, and
were given a score of 1.
Genotype analysis
Pulsed-ﬁeld gel electrophoresis (PFGE) of genomic DNA
digested with XbaI (Takara Bio Inc., Otsu, Japan) was per-
formed as previously described [17]. For isolates not type-
able with conventional methods, the bacterial pellet was
treated with 4% (v/v) formaldehyde in 10 mM Tris-HCl
(pH 7.5) and 1 M NaCl for 1 h at 4C before lysis [18]. The
restriction patterns were analysed with an established proto-
col [19]. A ‘clonal group’ was deﬁned as a group of isolates
consisting of more than one isolate whose restriction pat-
tern differed by no more than three bands. Singletons were
deﬁned as the isolates that did not belong to any clonal
group.
Enterobacterial repetitive intergenic consensus (ERIC)
PCR was also performed [20]. The ampliﬁcation primers
chosen for our assessment were ERIC1 (5¢-ATGTAAGCTC
CTGGGGATTCAC-3¢) and ERIC2 (5¢-AAGTAAGTGACTG
GGGTGAGCG-3¢). Thermocycling was performed with a
TaKaRa PCR Thermal Cycler SP (Takara Bio Inc.), and con-
sisted of the following steps: initial denaturation (95C,
15 min), 40 cycles of denaturation (95C, 30 s), annealing
(50C, 1 min), and extension (72C, 1 min), and a single ﬁnal
extension (72C, 15 min). Isolates were considered to
belong to a particular genotypic group on the basis of the
criteria described previously [21].
Statistical analysis
The relationships between two categorical variables were
analysed with the chi-squared test or Fisher’s exact test. The
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relationships between the categorical and ordinal variables
were determined with the Mann–Whitney U-test. The
correlation between two ordinal variables was assessed by
Spearman’s rank correlation coefﬁcient. Differences in a con-
tinuous variable among categories were analysed by Kruskal–
Wallis test. p-Values were two-tailed, and were considered
to be signiﬁcant when <0.05. All analyses were performed
with StatView version 5.0 (SAS Institute, Cary, NC, USA).
Results
Bacterial isolates
Sixty-two clinical isolates of E. cloacae were collected from
42 surgical inpatients at Kyoto University Hospital during the
7-month study period. Forty isolates were obtained from 22
liver transplant recipients, and the others were from 20
patients who had undergone other forms of abdominal sur-
gery. Twenty-nine of the 62 isolates (47%) were obtained
from ten patients from whom E. cloacae was detected
repeatedly.
Mutation frequencies of E. cloacae
The mutation frequencies were determined for 59 isolates,
because three of the original 62 isolates (one each from a
surgical site, sputum, and urine) exhibited resistance to rif-
ampicin at 100 mg/L. The mutation frequency of Escherichia
coli ATCC 25922 was determined to be 1.7 · 10)8, which is
compatible with previous reports of non-mutator Escherichia
coli [6,7,16].
The mutation frequencies of the 59 isolates ranged from
5.8 · 10)9 to 8.0 · 10)6, with a median of 5.0 · 10)8
(Fig. 1). The mutation frequency of E. cloacae ATCC 13047
was determined to be 8.0 · 10)9, so that seven (12%) iso-
lates were classiﬁed as strong mutators (i.e. mutation fre-
quencies >4.0 · 10)7), 30 (51%) as weak mutators (i.e.
mutation frequencies >4.0 · 10)8 and £4.0 · 10)7), and 22
(37%) as non-mutators (i.e. mutation frequencies
£4.0 · 10)8).
Mutators, antimicrobial resistance, and the sources of
recovery
The mutation frequency scores and the MICs of the antimi-
crobials correlated positively for piperacillin–tazobactam
(p 0.02, Spearman’s rank correlation), ceftazidime (p 0.007),
imipenem (p 0.04), and levoﬂoxacin (p 0.04) (Table 1). The
isolates with higher mutation frequency scores were resis-
tant to signiﬁcantly more antimicrobials (median numbers of
antimicrobials to which the isolates were resistant were two
among strong mutators, one among weak mutators, and zero
among non-mutators; p 0.0078). The isolates resistant to
more than two antimicrobials were signiﬁcantly more fre-
quent among strong mutators (3/7, 43%) than among the
other categories (3/52, 5.8%) (p 0.013).
The sources of recovery of the 59 isolates were as fol-
lows: 39 surgical site specimens (66%), 11 sputum specimens
(19%), ﬁve urine specimens (8%), three blood specimens
(5%), and one central venous catheter (2%). Four of the
seven (57%) strong mutators were recovered from surgical
sites, and three (43%) were recovered from sputa. There
were no signiﬁcant differences in the distribution of the
sources among strong mutators, weak mutators, and non-
mutators.
Genotype and its correlation with mutation frequency
The PFGE patterns of 55 of the 59 E. cloacae isolates were
classiﬁed into 36 pulsotypes. The remaining four isolates
showed only smearing on PFGE, even after re-examination
with modiﬁed pretreatment. These four isolates were analy-
sed only with ERIC PCR, and exhibited four distinct patterns
that were different from those of the rest of the isolates.
Thus, we classiﬁed them as singletons.
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FIG. 1. Distribution of the mutation fre-
quencies of 59 Enterobacter cloacae clinical
isolates. Range, 5.8 · 10)9 to 8.0 · 10)6;
median, 5.0 · 10)8. *Mutation frequency
of E. cloacae ATCC 13047 (8.0 · 10)9).
**Mutation frequency of Escherichia coli
ATCC 25922 (1.7 · 10)8).
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Five clonal groups (groups A, B, C, D, and E) were identi-
ﬁed by this genotyping, and the number of isolates within
each clonal group ranged from two to eight. The mutation
frequencies within each clonal group varied 116-fold in
group A (Fig. 2). The differences in mutation frequencies
among the ﬁve clonal groups were not statistically signiﬁcant
(p 0.28, Kruskal–Wallis test). Each of the seven strong muta-
tors exhibited a distinct genotype.
The characteristics of patients associated with detection of
strong mutators
Seven strong mutators were isolated from four patients. On
comparison of these four patients with the rest of the 38
patients from whom no strong mutators were obtained,
there were four statistically signiﬁcant characteristics associ-
ated with detection of strong mutators: history of ICU
admission (2/4 vs. 1/38, p 0.02, Fisher’s exact test), adminis-
tration of glycopeptides (3/4 vs. 6/38, p 0.036), administra-
tion of more than one category of antimicrobials (3/4 vs. 8/
38, p 0.049), and repetitive detection of E. cloacae (3/4 vs. 1/
38, p 0.039).
Mutation frequency and the genotype of the isolates
obtained from patients with repetitive detection of the
species
More than one isolate of a single genetic group was obtained
from three of the ten patients with repetitive detection of
E. cloacae. The isolates obtained from two of these three
patients included mutators (a strong mutator from one
patient, and a weak mutator from the other), but both of
these mutators were detected earlier than the non-mutators.
There were no patients from whom strong or weak muta-
tors belonging to a speciﬁc clonal group were repetitively
isolated.
The sources of the 29 isolates obtained from the ten
patients with repetitive detection of E. cloacae were as fol-
lows: surgical site specimens (21, 72%), sputum (4, 14%),
blood (3, 10%), and urine (1, 3%). There were no signiﬁcant
differences in sources between the isolates from these ten
patients and the others.
Discussion
To the best of our knowledge, this is the ﬁrst study to inves-
tigate the mutation frequencies of E. cloacae clinical isolates
and their clinical signiﬁcance. Our analysis showed that
strong mutators accounted for seven (12%) of 59 nosocomial
isolates of E. cloacae. This percentage is almost twice as high
TABLE 1. Comparison of MICs of antimicrobials among the
strong mutator, weak mutator and non-mutator isolates of
Enterobacter cloacaea
Agent MIC
Overall,
(n = 59)
Mutators
pc
Strong
mutators,
(n = 7)
Weak
mutators,
(n = 30)
Non-
mutators,
(n = 22)
TZP MIC50
b 16 128 16 2 <0.05
MIC90 128 128 128 128
CAZ MIC50 32 64 32 1 <0.01
MIC90 64 64 64 64
IPM MIC50 0.5 0.5 0.5 0.5 <0.05
MIC90 1 32 8 4
GEN MIC50 1 32 1 1 0.1
MIC90 32 32 2 32
LVX MIC50 2 2 0.25 0.25 <0.05
MIC90 4 16 2 4
TZP, piperacillin–tazobactam; CAZ, ceftazidime; IPM, imipenem; GEN, gentami-
cin; LVX, levoﬂoxacin.
aFor deﬁnition of strong mutators, weak mutators, and non-mutators, see text.
bThe MIC was determined according to the guidelines of the CLSI [14].
cSpearman’s rank correlation.
1.0 × 10–4
1.0 × 10–6
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Clones (number of isolates)
A
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1.0 × 10–8FIG. 2. Distribution of the mutation fre-
quencies within the clonal groups and sin-
gletons. Filled circles: strong mutators.
Open circles: weak mutators. Crosses:
non-mutators.
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as those reported for Escherichia coli and Salmonella by LeCl-
erc et al. [16], and is 10–20 times as high as the incidence of
natural Escherichia coli mutators [6,7]. This high prevalence
did not come from clonal spread of mutators or repetitive
detection of persistent mutator strains from particular
patients, because all of the seven mutators belonged to dis-
tinct genotypes.
Higher mutation frequency was correlated with higher
MICs of antimicrobials and resistance to more antimicrobials.
This is consistent with the association of mutator phenotype
and antimicrobial resistance reported for P. aeruginosa muta-
tors isolated from patients with chronic lung diseases [9].
Two of the four patient background factors associated
with detection of strong mutators were related to antimicro-
bial exposure, which may have provided a favourable micro-
environment for the resistant mutators. Consumption of
broad-spectrum antimicrobials is much higher among liver
transplant patients than among other surgical patients, proba-
bly because of the high incidence of infectious complications
in liver transplant recipients. In our hospital, most liver trans-
plant surgery is living-donor liver transplantation, in which
infectious complications are more frequent than in cadaveric
transplantation [22]. It is possible that more resistant muta-
tors were selected in such patients.
Repetitive detection of E. cloacae was another factor signif-
icantly associated with detection of mutators. However, in
contrast to the previous reports of P. aeruginosa mutators
[9,15], our mutator isolates appeared to have emerged by
replacing other clones during the clinical course. This differ-
ence may result from the difference between two species
and/or of the focus of infection. It is possible that a group of
mutators with increased adaptability may play a role in main-
taining a favourable microenvironment for this species, lead-
ing to prolonged infection with a genotypically heterogeneous
population.
It is also possible that ancestral non-mutators evolved into
mutators within each patient, as shown for P. aeruginosa [15].
The ﬁnding that the mutation frequency within a clonal
group varied as much as 116-fold is consistent with this
hypothesis; however, pairs of a mutator and a non-mutator
belonging to the same clonal group were obtained from only
two patients, and the detection of the mutator preceded
that of the non-mutator in both cases.
Another possibility is that there is an environmental reser-
voir of permanent mutators in nosocomial settings. An asso-
ciation of a history of ICU admission with detection of
strong mutators may support this hypothesis, although the
number of such patients was small. Further investigations
including environmental isolates would help to verify this
hypothesis.
Our study has some limitations. First, the number of iso-
lates was small, and they were obtained only from surgical
inpatients. We chose this population because more than
two-thirds of all E. cloacae isolates in our hospital are
derived from these patients. Although the high prevalence of
mutators associated with multiple antimicrobial resistance is
remarkable, the assessment of the clinical factors affecting
mutation frequencies may have been limited.
Second, the molecular mechanisms involved in the higher
mutation frequency were not investigated. Our primary aim
was to determine the mutation frequencies of E. cloacae and
their association with antimicrobial resistance and patient
factors, so the molecular mechanisms are beyond the scope
of this study.
In conclusion, strong mutators are highly prevalent among
surgical isolates of E. cloacae. The elevated mutation fre-
quency was associated with antimicrobial resistance and
repetitive detection, and may contribute to the adaptability
of this species in nosocomial settings.
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